PositoAI/ US/ C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

NasdaqGS: CCCC · Healthcare

Positivity Index

#4,088 / 6,774

Global

#1,957 / 4,000

United States

Positivity Score

19,934

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

C4 Therapeutics, Inc. — Overview & Financial Snapshot

C4 Therapeutics, Inc. (NasdaqGS: CCCC) is a Healthcare company, ranked #4,088 of 6,774 companies globally and #1,957 of 4,000 in United States on PositoAI, with a Positivity Score of 19,934. Its market capitalisation is ₹3,692.76 Cr ($391.22M), P/E ratio is -3.5 and P/B ratio is 1.58. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

P/B Ratio 1.58

P/E Ratio -3.5

D/E Ratio 0.23

ROE -48.14%

Owes vs Owns ? 0.31× Low $0.31 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-85.90$-0.91

Forward EPS ₹-90.80$-0.96

Beta 3.08

Market Cap ₹3,692.76 Cr$391.22M

What these numbers mean →

What does C4 Therapeutics, Inc. do?

What is C4 Therapeutics, Inc.'s P/E and P/B ratio?

C4 Therapeutics, Inc. has a P/E ratio of -3.5 and a P/B ratio of 1.58.

What is C4 Therapeutics, Inc.'s debt-to-equity ratio?

C4 Therapeutics, Inc. has a debt-to-equity ratio of 0.23.

How much does C4 Therapeutics, Inc. owe compared with what it owns?

C4 Therapeutics, Inc. owes $0.31 for every $1 it owns (balance sheet Jun 2026), which is low.

What is C4 Therapeutics, Inc.'s Positivity rank?

C4 Therapeutics, Inc. is ranked #4,088 of 6,774 companies globally and #1,957 of 4,000 in United States on PositoAI, with a Positivity Score of 19,934.

Does C4 Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for C4 Therapeutics, Inc..

Where can I read the latest news about C4 Therapeutics, Inc.?

Recent headlines about C4 Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does C4 Therapeutics, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of C4 Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.